Takeda announces approval of takhzyro® (lanadelumab) subcutaneous injection in china for the treatment of hereditary angioedema

Shanghai & osaka, japan--(business wire)--takeda announces approval of takhzyro® (lanadelumab) subcutaneous injection in china for the treatment of hereditary angioedema

TAK Ratings Summary

TAK Quant Ranking